大剂量羟考酮在肿瘤晚期患者中止痛治疗的临床分析  

Clinical analysis of high dose of oxycodone in the treatment of pain in patients with advanced cancer

作　　者：李娜[1] 王玉梅[1] 郑暄[1] 崔檬[1] 

机构地区：[1]中国医科大学附属盛京医院宁养病房,沈阳110004

出　　处：《实用药物与临床》2017年第2期184-188,共5页Practical Pharmacy and Clinical Remedies

基　　金：辽宁省教育厅课题(L2014314)

摘　　要：目的研究不同剂量羟考酮在肿瘤晚期患者中的使用效果,尤其是大剂量羟考酮的安全性。方法对我院宁养病房2011年1月至2016年6月期间住院应用羟考酮的295例恶性肿瘤晚期患者进行回顾性分析及随访,将患者分成小剂量组(<30 mg)、中等剂量组(30~149 mg)及大剂量组(≥150 mg),收集患者的一般资料及临床数据,并对其进行统计分析。结果 43例晚期肿瘤患者使用大剂量羟考酮,与小剂量组及中等剂量组比较,不良反应及生存期差异无统计学意义(P>0.05)。其中妇科恶性肿瘤、骨转移、骨痛及神经病理性疼痛患者需要更大剂量的羟考酮,差异有统计学意义。结论羟考酮可有效控制恶性肿瘤晚期患者的癌痛,对传统剂量效果不佳的患者,大剂量羟考酮安全有效,不缩短患者的生存期。Objective To analyze the efficacy of different doses of oxycodone for patients with advanced cancer,and to observe the safety of high-dose oxycodone.Methods Totally 295 patients with advanced cancer in hospice ward of our hospital from January 2011 to June 2016 were retrospectively analyzed and followed up.The patients were divided into low-dose group（〈30 mg）,mid-dose group（30~149 mg） and high-dose group（≥150 mg）.The general information and clinical data of patients were analyzed and compared among the three groups.Results There were 43 patients with advanced cancer in high-dose group.There was no significant difference in the adverse reaction and survival time between high-dose group and low-dose group（or mid-dose group）（P〉 0.05）.Patients with gynecological malignant tumors,bone metastasis,bone pain and neuropathic pain needed high-dose oxycodone.Conclusion Oxycodone can effectively control the cancer pain of patients with advanced cancer;high-dose oxycodone is safe and effective for the patients with poor efficacy who have been treated by conventional dose of oxycodone,and does not shorten the survival time.

关 键 词：羟考酮 肿瘤晚期 不良反应 生存期 

分 类 号：R730.5[医药卫生—肿瘤]